Blue Earth Therapeutics has announced promising results from their Phase 1 trial of Lutetium (177Lu) rhPSMA-10.1 Injection for metastatic prostate cancer. The trial data indicates significantly higher radiation doses to tumors compared to critical healthy tissues, suggesting the potential for improved patient outcomes. The Phase 2 trial is set to begin soon, aiming to maximize radiation delivery to tumors while minimizing toxicity to normal organs. CEO David Gauden emphasized the innovative approach of their treatment, which could greatly benefit prostate cancer patients. The trial follows increasing recognition of the challenges in treating metastatic prostate cancer, which has a notably low five-year survival rate.
Thu, 13 Mar 2025 12:00:00 GMT | PR Newswire